Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

First Biosimilar Drugs Approved in U.S., Canada

Michele B. Kaufman, PharmD, BCGP  |  May 15, 2015

The first biosmilar products have been approved in the U.S. and Canada, following Europe’s early lead. Canada approved its first biosimilar monoclonal antibody (mAb) therapy, known as Inflectra (infliximab), on March 30, 2015.1 In Canada, biosimilars are being called subsequent entry biologic (SEB) agents. Inflectra is approved for treating patients with rheumatoid arthritis (RA), ankylosing…

Filed under:Biologics/DMARDsDrug Updates Tagged with:Biologics & BiosimilarsDrug Updates

Figures 1 & 2: On exam, the patient had thickening of the skin on her extremities.

Dermatology Symptoms Point to Connective Tissue Disorder

Natalie A. Wright, MD, and Joseph F. Merola, MD, MMSc, FAAD, FACR  |  May 15, 2015

The Case A 68-year-old woman with a past medical history of Charcot-Marie-Tooth presents with thickening of the skin on her trunk and extremities, which she has had for the past seven months (see Figures 1 and 2). Her symptoms first began with swelling of her bilateral upper and lower extremities. She is now having difficulty…

Filed under:ConditionsSystemic Sclerosis Tagged with:connective tissue disorderDermatologyeosinophilic fasciitis

Letters: Biomarkers for Rheumatoid Arthritis

Ronald van Vollenhoven, MD, PhD  |  May 15, 2015

Biomarkers for RA I read the article, “Finding Biomarkers in RA Remains Elusive Goal” (February 2015 The Rheumatologist), with great interest. The author correctly identifies the multi-biomarker disease activity assay (MBDA; Vectra DA) as a potential biomarker that identifies RA patients at risk for radiographic progression. The author names a study presented at the 2014…

Filed under:ConditionsRheumatoid Arthritis Tagged with:BiomarkersRheumatoid arthritisviewpoint

Plaquenil: From Malaria Treatment to Managing Lupus, RA

Charles Radis, DO  |  May 15, 2015

In 1984, I wrote my first prescription for the antimalarial drug, hydroxychloroquine (Plaquenil), for a 28-year-old woman with SLE. She was considerably overweight, with inflammatory arthritis and a photosensitive rash, and I worried that oral corticosteroids would tip her over into diabetes. I presented the case to my attending, Steven Malawista, MD, at the Yale…

Filed under:ConditionsDrug UpdatesRheumatoid ArthritisSystemic Lupus Erythematosus Tagged with:drugLupusPlaquenilRheumatoid arthritis

Dr. Kumar

Meet the Editors

The editorial staff of The Rheumatologist comprises medical and publishing professionals. Physician Editor Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS, is a clinical associate professor of internal medicine in the Division of Immunology, University of Iowa Hospitals and Clinics, Iowa City. Before assuming the role of physician editor, he was a member of the ACR…

Health Data Breaches on the Rise

Kathryn Doyle (Reuters Health)  |  April 15, 2015

Large-scale health data breaches reported by doctors and health plans have been rising steadily, a new report shows. From 2010 to 2013, nearly 1000 large breaches affected more than 29 million individual health records, and more than half resulted from theft or loss of laptops, thumb drives and paper records, according to researchers with access…

Filed under:Practice Support Tagged with:Electronic health recordsprivacySecurity

Imaging in Ankylosing Spondylitis

Susanne Juhl Pedersen, MD, PhD  |  April 1, 2015

MRI inflammation, fat and new bone formation in the sacroiliac joints, spine in patients with AS

Filed under:Axial SpondyloarthritisConditions Tagged with:Ankylosing SpondylitisbonefatimaginginflammationMRIrheumatologysacroiliac jointsspine

Biosimilar for Infliximab Launched in Europe

Michele B. Kaufman, PharmD, BCGP  |  April 1, 2015

Plus, updates on arhalofenate, ALO-02, and other rheumatology drug news, safety information

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiosimilarsDrugsFDAinfliximabKaufmanrheumatologySafety

Tech Talk: HealthPatch MD Latest in Wearable Health Devices

Thomas R. Collins  |  April 1, 2015

HealthPatch, Body Guardian, other wearable cardiac monitors could be considered for wider use among patients with rheumatoid arthritis

Filed under:Technology Tagged with:cardiovascular eventCollinspatient careRheumatoid arthritisriskTechnologywearable device

2014 ACR/ARHP Annual Meeting: Macrophage Activation Syndrome

Mary Beth Nierengarten  |  April 1, 2015

The pathogenesis of and new classification criteria for MAS

Filed under:ConditionsOther Rheumatic ConditionsResearch Rheum Tagged with:ACR/ARHP Annual Meetingcytokine storm syndromemacrophage activation syndromeNierengartenResearchRheumatic Disease

  • « Previous Page
  • 1
  • …
  • 244
  • 245
  • 246
  • 247
  • 248
  • …
  • 324
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences